First Patient Dosed in the Ph 3 Registrational Trial of ICP-248 + Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China April 2, 2025
Multikine Confirmatory Ph 3 Trial in newly diagnosed locally advanced head and neck cancer patients to be Initiated March 18, 2025
VERSATILE-003 Ph 3 Trial of Versamune HPV in HPV16-Positive Head and Neck Cancer Initiated March 11, 2025
Patient Enrollment completed in Ph 3 Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent HCC March 11, 2025
Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients in final stage of start-up preparations March 11, 2025
First Patient Dosed in Dauntless-1 Ph 2 Clinical Trial of PMD-026 in Combination with Fulvestrant for RSK2-high Breast Cancer March 11, 2025
Plans announced for Ph 2 trial of stenoparib + temozolomide for the treatment of recurrent SCLC March 11, 2025
Independent Data Monitoring Committee (DMC) recommends a dose increase in the ongoing Ph 1/2a study TUMORAD-01 of 177Lu-SN201 March 11, 2025
Enrollment Completed in Ph 2 Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China March 11, 2025
Clinical Trial Application Submitted in Australia for CS5001 in Combination with 1L SOC for DLBCL March 11, 2025
First New Subject Dosed in Ph 2 Study of Ampligen and Imfinzi Combination Therapy for Late-Stage Pancreatic Cancer March 4, 2025
First Dose Cohort in STARLIGHT-1 Trial Completed and Approval Received to Initiate Higher Dose Cohort March 4, 2025
